Blood Cancer Awareness
Oncology | Blood cancer

Nurturing advances in oncohematology

QIAGEN's oncohematology solutions bring innovation in molecular testing to patients, faster and without compromise. We support your path to personalized blood cancer care and advancements in molecular research with a comprehensive assay, platform and service portfolio – from Sample to Insight.
icon-contact
Contact an expert
Discover how QIAGEN can help you and your patients.

Improve diagnosis and treatment monitoring

Your partner for blood cancer  companion diagnostics

Your partner for blood cancer companion diagnostics

Successful companion diagnostic (CDx) and drug co approval requires the right partner. QIAGEN has a proven track record in IVD development, global regulatory capabilities and global commercialization expertise.

Test with confidence

QIAGEN's extensive oncohematology portfolio includes multiple solutions for highly sensitive and accurate leukemia biomarker detection and/or quantification. Test with ipsogen, for results you can trust.

ipsogen real-time PCR blood cancer assays

ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; CML: Chronic myeloid leukemia; CNV: Copy number variation; InDel: Inserstions/deletions; IS: International Scale; MPN: Myeloproliferative neoplasms; MRD: Minimal residual disease; NGS: Next-generation sequencing; Ph: Philadelphia chromosome; SNV: Single nucleotide variation.

The ipsogen JAK2 RGQ PCR Kit, ipsogen CALR RGQ PCR Kit, ipsogen BCR-ABL1 Mbcr RGQ RT-PCR Kit, ipsogen BCR-ABL1 mbcr Kit,  ipsogen PML-RARA bcr1 Kit and ipsogen WT1 ProfileQuant Kit are intended for in vitro diagnostic use.

QIAseq Panels are intended for molecular biology applications. These products are not intended for the diagnosis, prevention, or treatment of a disease.

QCI Interpret is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic next-generation sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases, annotations, drug labels, and clinical-trials. Based on this evaluation, the software proposes a classification and bibliographic references to aid in the interpretation of observed variants. The software is NOT intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national, and local clinical laboratory regulations and other specific accreditations requirements.

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual. QIAGEN kit handbooks and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services or your local distributor. QIAGEN is the exclusive licensee of intellectual property rights that cover the detection of the V617F JAK2 mutation (EP 1 692 281 and foreign counterparts) and CALR mutations (EP 2 808 338 and foreign counterparts) for diagnostic purposes.

X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
Confirm